Angiotensin IV: Mechanism, Dosing & Research Data

Angiotensin IV (Ang IV) is the hexapeptide fragment of the renin-angiotensin system formed by sequential aminopeptidase cleavage of Ang II and Ang III. Unlike its precursors, Ang IV acts primarily through the AT4 receptor (IRAP, insulin-regulated aminopeptidase) in brain, kidney, and cardiovascular tissue to enhance memory consolidation, promote natriuresis, and regulate regional blood flow in the CNS.

Mechanism of Action

IRAP (AT4 receptor) is a membrane-bound aminopeptidase; Ang IV binds its catalytic site, inhibiting IRAP peptidase activity and liberating endogenous IRAP substrates (oxytocin, vasopressin, enkephalin/" class="wiki-internal-link">Met-enkephalin)
In hippocampus: IRAP inhibition by Ang IV reduces oxytocin degradation, increasing local oxytocin availability and enhancing synaptic plasticity and LTP
Memory enhancement: Ang IV increases cGMP/NO signaling in hippocampal neurons, facilitating long-term potentiation (LTP) and spatial memory consolidation
Renal: Ang IV at AT4 receptor increases glomerular filtration and natriuresis; counterbalances Ang II-mediated sodium retention
Cerebrovascular: Ang IV dilates cerebral arterioles and increases cerebral blood flow; may protect against ischemic damage

Research Findings

ICV or hippocampal Ang IV improved learning in passive avoidance and water maze tests in normal and scopolamine-amnesic rats
Ang IV overcomes memory impairment induced by AT1R blockade and Ang II infusion in rodent cognition models
IRAP knockout mice show impaired spatial memory and reduced hippocampal oxytocin levels, confirming IRAP/Ang IV memory role
LVV-hemorphin-7 and Ang IV both inhibit IRAP, suggesting a broader oxytocin/vasopressin-sparing mechanism for cognitive enhancement
Small molecule IRAP inhibitors developed from Ang IV pharmacophore show memory enhancement without peptide delivery limitations

Research Protocols

Memory: 10-100 nmol ICV or 0.1-1 nmol direct hippocampal infusion in rats; assess recall in Morris water maze or passive avoidance
Renal: 1-10 pmol/kg/min IV infusion in conscious instrumented rats; measure GFR by inulin clearance and sodium excretion
IRAP inhibition: Ang IV at 0.1-10 mcM on purified IRAP or membrane preparation; measure residual aminopeptidase activity by fluorogenic substrate
Cerebrovascular: intravitreal or topical cortical application of 1-10 nM Ang IV; measure arteriolar diameter by intravital microscopy

Interactions

Angiotensin II and III: precursors in the RAS cascade; Ang IV is their downstream metabolite with distinct receptor pharmacology
Oxytocin and vasopressin: IRAP inhibition by Ang IV indirectly spares these neuropeptides from degradation, producing secondary cognitive effects
AT1R blockers (losartan, olmesartan): shift Ang II processing toward Ang IV; may partly explain cognitive benefits of ARBs in dementia prevention studies

Safety Profile

Endogenous RAS metabolite. Not clinically used. ICV and peripheral doses in rodents well tolerated; no reported organ toxicity. Potential cognitive enhancement applications drive small molecule IRAP inhibitor development.